---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-22-088622"
form_type: "8-K"
ticker: "TELA"
cik: "0001561921"
company_name: "TELA Bio, Inc."
filed_at: "2022-08-10T23:59:59+00:00"
generated_at: "2026-06-24T01:24:44.072543+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# TELA Bio Q2 revenue $10.4M (+38% YoY); FY2022 guidance $42-45M

## Summary
- Q2 revenue of $10.4M, up 38% YoY; OviTex revenue +22%, OviTex PRS +87%.
- Net loss widened to $12.7M from $8.3M; operating loss $10.2M vs $7.3M.
- FY2022 revenue guidance $42-45M (43-53% growth); COVID could impact.
- Cash $27.7M at June 30; secured up to $50M debt facility from MidCap Financial.
- Entered GPO contract with Premier Inc. covering ~4,400 hospitals, effective October 2022.

## SEC filing metadata
- accession: 0001104659-22-088622
- form_type: 8-K
- ticker: TELA
- cik: 0001561921
- company_name: TELA Bio, Inc.
- filed_at: 2022-08-10T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1561921/000110465922088622/0001104659-22-088622-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1561921/000110465922088622/tm2223031d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-22-088622
- JSON: https://secwatch.observer/filing/0001104659-22-088622.json
- Plain text: https://secwatch.observer/filing/0001104659-22-088622.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.